drugset / Trial / NCT01932437
Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
RandomizedSequentialTriple-blindOther
Summary
This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers
Timeline
- Start
- 2013-07-26
- Primary completion
- 2014-07-03
- Completion
- 2014-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obiltoxaximab | Monoclonal antibody | 4 mg/kg | Intramuscular |
| Subject | Obiltoxaximab | Monoclonal antibody | 8 mg/kg | Intramuscular |
| Subject | Obiltoxaximab | Monoclonal antibody | 16 mg/kg | Intramuscular |
| Subject | Obiltoxaximab | Monoclonal antibody | 20 mg/kg | Intramuscular |
| Subject | Obiltoxaximab | Monoclonal antibody | 24 mg/kg | Intramuscular |